期刊文献+

丙磺舒对头孢克罗肠道吸收的影响(英文)

Effects of probenecid on intestinal absorption of cefaclor in rats
下载PDF
导出
摘要 目的:研究不同剂量丙磺舒联用对头孢克罗肠道吸收的影响及其可能机制。方法:(1)药代动力学试验:头孢克罗(100mg/kg)对大鼠静脉给药,分别与不同剂量丙磺舒(0、300、600、900mg/kg)联用,HPLC监测用药后不同时间的血药浓度,DAS软件计算头孢克罗的药代动力学参数。(2)肠道吸收试验:头孢克罗(30μg/mL)分别与不同剂量丙磺舒(0、90、180、270μg/mL)联用,对大鼠在体肠回流给药,给药后不同时间采样,HPLC测定灌流液中头孢克罗浓度的经时变化。结果:(1)头孢克罗静脉给药的血药浓度-时间曲线呈二室开放模型;在试验剂量范围内,随丙磺舒联用剂量增大,头孢克罗的血药浓度呈剂量依赖性增高;AUC与丙磺舒联用剂量呈正相关(r=0.997),而Cl、Vd及V1与丙磺舒联用剂量呈负相关(r=-0.837,-0.817及-0.888)。(2)大鼠在体肠回流实验表明,不同剂量丙磺舒联用对头孢克罗肠道吸收影响的程度不同,当丙磺舒联用剂量达270μg/mL水平时,灌流液内头孢克罗的留存率明显增高。结论:与适量丙磺舒联用,头孢克罗分布容积及血浆清除率降低,血药浓度增高;而与大剂量丙磺舒联用则明显延缓或抑制头孢克罗的肠吸收,使头孢克罗血药浓度降低,该现象可能与大剂量丙磺舒抑制头孢克罗的肠道吸收有关,其机制有待进一步阐明。 AIM:To investigate the effect of probenecid on intestinal absorption of cefaclor and possible mechanisms involved.METHODS:Pharmacokinetic experiments:cefaclor(100 mg/kg,i.v.)was given alone or in the presence of probenecid(300,600 and 900 mg/kg,i.g.)to rats.Plasma concentrations of cefaclor were determined by HPLC and the corresponding parameters were calculated with DAS software.Intestinal absorption experiment:cefaclor(30 μg/mL)was co-administered with different dosages of probenecid(0,90,180 and 270 μg/m...
出处 《中国临床药理学与治疗学》 CAS CSCD 2008年第12期1344-1349,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 丙磺舒 头孢克罗 药动学 吸收 HPLC probenecid cefaclor pharmacokinetics absorption HPLC
  • 相关文献

参考文献2

二级参考文献16

  • 1程能能 孙瑞元.新药数据的统计处理及NDST程序[J].皖南医学院学报,1994,13:28-30.
  • 2Levison ME,Santoro J,Ayarwal BN.In vitro activity and pharmacokinetics of cefaclor in normal volunteer and patients with renal failure[J].Postgrad Med J,1979;55 (Supple4):12-6
  • 3Kitaura T,Tsukiai S,Miyake K,et al.Ocular Pharmacokinetics of Latamoxef and cefaclor in rabbits[J].J Pharmacobiodyn ,1988; 11:694-9
  • 4Cunningham RF,Israili ZH,Dayton PG.Clinical Pharmacokineftcs of probenecid[J].Clin Pharmacokinet,1981;6:135-51
  • 5Tsuji A,Terasai T,Tanai I,et al.In vitro evidence for carrier-mediated uptake of B-lactam antibiotics through organic anion transport systems in rat kidney and liver[J].J Pharmacol Exp Ther,1990;253:315-20
  • 6Bonate PL,Reith K,Weir S.Drug interactions at the renal level[J].Clin pharmacokinet,1998;34:375-404
  • 7Barbhaiya RH,Shukla UA,Gleason CR,et al.Phase I study of multiple-dose cefprozil and comparsion with cefaclor[J].Antimicrob Agens Chemother,1990;34:1198-203
  • 8Sourgens H,Derendorf H,Schifferer H,et al.Pharmacokinetic profile of cefaclor[J].Int J Clin Pharmacol Ther,1997;35:374-80
  • 9Selen A,Amidon GL,Welling PG,et al.Pharmacokinetics of probenecid following oral doses to human volunteers[J].J Pharm Sci,1982;71:1238-42
  • 10Santoro J,Agarwal BN,Martinelli R,et al.Pharmacology of cefaclor in normal volunteers and patients with renal failure[J].Antimicrob Agens Chemother,1978;13:951-4

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部